{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:22:23Z","timestamp":1784910143452,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.vaccine.2021.06.069","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T18:07:26Z","timestamp":1625162846000},"page":"4450-4457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A phase I\/II study to evaluate safety, tolerability and immunogenicity of Hillchol\u00ae, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh"],"prefix":"10.1016","volume":"39","author":[{"given":"Fahima","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Ali Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroza","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taufiqur","family":"Rahman Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam","family":"Tauheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Khaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajib","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannatul","family":"Ferdous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Al Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen G.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Mc Millan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhu","family":"Kanchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Pal Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nordqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Holmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10001","key":"10.1016\/j.vaccine.2021.06.069_b0005","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/S0140-6736(15)61140-0","article-title":"Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial","volume":"386","author":"Qadri","year":"2015","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2021.06.069_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108521","article-title":"Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co\u2013expressing the Inaba and Ogawa Lipopolysaccharide Antigens","volume":"9","author":"Karlsson","year":"2014","journal-title":"PLoS one"},{"key":"10.1016\/j.vaccine.2021.06.069_b0015","unstructured":"WHO. Cholera vaccines: WHO position paper. Weekly Epidemiological Record= Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire 2010 [cited 2021 13 January]; Available from: https:\/\/www.who.int\/wer\/2010\/wer8513.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2021.06.069_b0020","unstructured":"WHO. cholera GRADE evidence recommendation tables. [cited 2021 13 January]; Available from: https:\/\/www.who.int\/immunization\/policy\/position_papers\/cholera_GRADE_evidence_recommendation_tables.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2021.06.069_b0025","doi-asserted-by":"crossref","unstructured":"Desai, S.N., et al., Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era. 2017, Taylor & Francis.","DOI":"10.1080\/21645515.2016.1245250"},{"key":"10.1016\/j.vaccine.2021.06.069_b0030","unstructured":"GTFCC. Ending cholera A global roadmap to 2030. 2017 [cited 2021 13 January]; Available from: https:\/\/www.who.int\/cholera\/publications\/global-roadmap.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2021.06.069_b0035","unstructured":"Zambian Government commits to ending cholera by 2025. 2019 [cited 2021 13 January]; Available from: https:\/\/www.afro.who.int\/news\/zambian-government-commits-ending-cholera-2025."},{"issue":"43","key":"10.1016\/j.vaccine.2021.06.069_b0040","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1016\/j.vaccine.2011.06.121","article-title":"Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens","volume":"29","author":"Lebens","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.06.069_b0045","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/21645515.2017.1356525","article-title":"Safety of oral cholera vaccines during pregnancy in developing countries","volume":"13","author":"Khan","year":"2017","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"50","key":"10.1016\/j.vaccine.2021.06.069_b0050","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.1016\/j.vaccine.2020.10.043","article-title":"Development of Hillchol\u00ae, a low-cost inactivated single strain Hikojima oral cholera vaccine","volume":"38","author":"Sharma","year":"2020","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2021.06.069_b0055","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1016\/j.vaccine.2011.08.108","article-title":"Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age","volume":"29","author":"Saha","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.06.069_b0060","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/wics.155","article-title":"Sample size calculations for clinical trials","volume":"3","author":"Chow","year":"2011","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"issue":"18","key":"10.1016\/j.vaccine.2021.06.069_b0065","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1510330","article-title":"Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh","volume":"374","author":"Qadri","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2021.06.069_b0070","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4269\/ajtmh.14-0095","article-title":"Bacterial shedding in household contacts of cholera patients in Dhaka, Bangladesh","volume":"91","author":"Weil","year":"2014","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"8","key":"10.1016\/j.vaccine.2021.06.069_b0075","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1128\/IAI.71.8.4808-4814.2003","article-title":"Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers","volume":"71","author":"Qadri","year":"2003","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2021.06.069_b0080","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1128\/iai.65.9.3571-3576.1997","article-title":"Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1","volume":"65","author":"Qadri","year":"1997","journal-title":"Infect Immun"},{"issue":"49","key":"10.1016\/j.vaccine.2021.06.069_b0085","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1016\/j.vaccine.2009.09.008","article-title":"Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial","volume":"27","author":"Kanungo","year":"2009","journal-title":"Vaccine"},{"issue":"9702","key":"10.1016\/j.vaccine.2021.06.069_b0090","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0140-6736(09)61297-6","article-title":"Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial","volume":"374","author":"Sur","year":"2009","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2021.06.069_b0095","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/oxfordjournals.aje.a113498","article-title":"Endemic cholera in rural Bangladesh, 1966\u20131980","volume":"116","author":"Glass","year":"1982","journal-title":"Am J Epidemiol"},{"issue":"26","key":"10.1016\/j.vaccine.2021.06.069_b0100","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.vaccine.2017.05.005","article-title":"Correlates of protection for enteric vaccines","volume":"35","author":"Holmgren","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.06.069_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096499","article-title":"Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India","volume":"9","author":"Kanungo","year":"2014","journal-title":"PloS one"},{"issue":"5","key":"10.1016\/j.vaccine.2021.06.069_b0110","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1128\/CVI.00562-10","article-title":"Antigen-specific memory B-cell responses in Bangladeshi adults after one-or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera","volume":"18","author":"Alam","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2021.06.069_b0115","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/INF.0b013e3181783adf","article-title":"A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh","volume":"27","author":"Chowdhury","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2021.06.069_b0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4269\/ajtmh.14-0683","article-title":"A randomized, placebo-controlled trial evaluating safety and immunogenicity of the killed, bivalent, whole-cell oral cholera vaccine in Ethiopia","volume":"93","author":"Desai","year":"2015","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"3","key":"10.1016\/j.vaccine.2021.06.069_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003574","article-title":"Flexibility of oral cholera vaccine dosing\u2014a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone","volume":"9","author":"Kanungo","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2021.06.069_b0130","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/iai.61.9.3994-3997.1993","article-title":"Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels","volume":"61","author":"Gotuzzo","year":"1993","journal-title":"Infect Immun"},{"issue":"8684","key":"10.1016\/j.vaccine.2021.06.069_b0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0140-6736(90)90080-O","article-title":"Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up","volume":"335","author":"Clemens","year":"1990","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2021.06.069_b0140","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/infdis\/149.6.884","article-title":"Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine","volume":"149","author":"Svennerholm","year":"1984","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.069_b0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1172\/JCI115270","article-title":"Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory","volume":"88","author":"Quiding","year":"1991","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.069_b0150","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/1471-2334-13-518","article-title":"Cost of illness for cholera in a high risk urban area in Bangladesh: an analysis from household perspective","volume":"13","author":"Sarker","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.06.069_b0155","unstructured":"WHO, Cholera vaccines: WHO position paper\u2013August 2017\u2013Vaccins antichol\u00e9riques: Note de synth\u00e8se de l\u2019OMS\u2013ao\u00fbt 2017. Weekly Epidemiological Record, 2017. 92(34): p. 477-498."},{"issue":"8","key":"10.1016\/j.vaccine.2021.06.069_b0160","doi-asserted-by":"crossref","first-page":"e1081","DOI":"10.1016\/S2214-109X(20)30310-7","article-title":"Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study","volume":"8","author":"Lee","year":"2020","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.vaccine.2021.06.069_b0165","doi-asserted-by":"crossref","unstructured":"Martin, S., A. Costa, and W. Perea, Stockpiling oral cholera vaccine. 2012, SciELO Public Health.","DOI":"10.2471\/BLT.12.112433"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21008306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21008306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:58:57Z","timestamp":1759402737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21008306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":33,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0264410X21008306"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I\/II study to evaluate safety, tolerability and immunogenicity of Hillchol\u00ae, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}